By Week 5, testosterone is on board. Trough levels are stable, estradiol is in range, libido is back, and the morning energy floor has lifted. Body composition has started to shift — but slower than expected, and sleep architecture is still off. That's the GH axis showing itself. Testosterone restores the androgen signal. It does almost nothing for the growth hormone collapse that runs parallel to it through your thirties and forties. The IGF-1 deficit is what's gating your recovery, your slow-wave sleep, your visceral fat loss, and the lean-mass yield you expected from training on optimized T. Phase 2 layers the GH axis on top of the androgen rebuild.
What's actually collapsing on the GH side
The pituitary doesn't stop producing growth hormone — it stops pulsing it. The natural rhythm is sharp, brief nocturnal bursts that drive overnight repair, fat oxidation, and slow-wave sleep depth. Those pulses flatten with age. IGF-1, the liver-produced downstream signal that proxies your total GH status, drops correspondingly. Practitioner consensus treats IGF-1 as the most reliable marker for overall GH activity — it's what you'll track, not GH itself, which is too pulsatile to measure usefully.
The intervention is not synthetic recombinant GH. Exogenous GH delivers a flat, unnatural bolus that suppresses your own pituitary output and carries real side-effect liability — edema, insulin resistance, carpal tunnel, joint pain. Secretagogues work the other direction: they signal your pituitary to release its own GH in physiologic pulses, preserving the negative-feedback loop. Two compound classes do this synergistically, and stacking them is where the body-composition leverage lives.
GHRH analogs (CJC-1295) mimic growth-hormone-releasing hormone. They amplify the upstream signal that tells the pituitary to release GH and also suppress somatostatin, the brake on GH release. GHRPs (Ipamorelin) bind the ghrelin receptor and trigger a sharp pulse of GH at the pituitary level. GHRH establishes the elevated baseline; the GHRP creates the discrete pulse on top of it. Run alone, each compound gives you part of the signal. Run together, you get sustained baseline plus sharp pulses — the closest synthetic approximation of youthful GH rhythm.
Ipamorelin is the GHRP of choice for this stack specifically because of what it doesn't do. The older GHRPs (GHRP-2, GHRP-6) cause significant prolactin and cortisol spillover — they raise GH but drag along hormones you spent Phase 1 carefully calibrating. Ipamorelin is the cleanest GH pulse available, with no meaningful cortisol or prolactin activation. On a TRT protocol where you've already tuned the HPA axis, that selectivity matters.
Why this stacks with TRT instead of fighting it
Testosterone and IGF-1 are the two main anabolic drivers, both supporting overlapping but distinct pathways. Testosterone optimizes androgen receptor signaling, protein synthesis, and red blood cell production. IGF-1 drives muscle hyperplasia, fat oxidation, and the overnight repair that turns training stimulus into adaptation. The recovery deficit most TRT-only men complain about by Week 8 — "training feels productive but the body isn't catching up" — is the missing IGF-1 layer.
The nighttime dose specifically stacks with your natural sleep-time GH surge for maximum output. The 2+ hour fasted window matters: elevated insulin from a recent meal blunts GH release. You're aligning the pulse with your body's own rhythm, not overriding it.
Protocol prescription — Phase 2 stack (Week 5-10)
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| CJC-1295 (no DAC / Mod GRF 1-29) | 100 mcg | Subcutaneous (abdomen) | 2x/day — AM fasted + PM pre-bed | 🟢 Expert | Pairs with each Ipamorelin shot. Short half-life is the feature, not a bug — preserves natural pulsatility |
| Ipamorelin | 100–200 mcg | Subcutaneous (abdomen) | 2x/day — AM fasted + PM pre-bed (2+ hr post-meal) | 🟢 Expert | Cleanest GHRP — no cortisol/prolactin spillover. Start 100 mcg, titrate to 200 mcg if tolerated |
| CJC-1295 DAC (alternative — once-weekly route) | 2 mg | Subcutaneous | 1x/week, any time of day | 🟢 Expert | 8+ day half-life. Simpler compliance but flatter pharmacokinetic profile than the no-DAC version |
| Testosterone (continued from Phase 1) | Per Phase 1 protocol | IM or SubQ | Per Phase 1 protocol | 🔵 Clinical | Do not adjust. GH stack layers on top, does not replace |
The no-DAC + Ipamorelin twice-daily protocol is the higher-fidelity choice for this Path. The short half-life of Mod GRF 1-29 means each dose creates a discrete window where GHRH signal and Ipamorelin's ghrelin-receptor pulse converge — closer to native rhythm than the flatter weekly DAC profile. The trade-off is injection burden: two shots a day on top of your TRT injection schedule. The Trilogy practitioner pattern uses a single combined draw — CJC-1295 and Ipamorelin pulled into the same insulin syringe and dosed together.
Cycle length: 10–12 weeks maximum. Practitioner consensus is clear on this: Ipamorelin at higher doses run beyond twelve weeks begins to desensitize the ghrelin receptor and blunt your own output. Run the full Phase 2 window, then cycle off for 4–6 weeks before reintroducing.
What you should feel — week by week
- Nights 3–7: Sleep depth increases. Deeper slow-wave sleep, more vivid dreams (REM rebound), waking less between cycles. This is the earliest and most reliable signal — if it doesn't appear within the first week, check injection technique and reconstitution math before assuming non-response.
- Week 2–3: Subjective recovery between training sessions improves. Soreness clears faster. Skin quality starts to firm — a subtle but consistent practitioner-reported marker.
- Week 4–6: IGF-1 elevation becomes measurable on bloodwork. This is the lab confirmation that the stack is working. Pull labs at the 6-week mark.
- Week 6–10: Visceral fat reduction becomes visible. Lean-mass yield from training accelerates. The body-composition shift that was stalled at end of Phase 1 starts moving.
What's NOT happening yet
- You're not getting a "GH high." Secretagogues restore physiologic pulses. There's no acute euphoria, no synthetic-GH water-weight surge in week 1. If you feel nothing acutely, that's the protocol working correctly.
- Visceral fat doesn't drop in week 1. Tesamorelin trial data on visceral adipose reduction reads out over months, not weeks. The CJC/Ipamorelin stack works on a similar timeline. Track waist circumference monthly, not weekly.
- IGF-1 won't move on a Week 2 blood draw. The 4–6 week window is when the lab signal becomes reliable. Drawing earlier wastes a panel.
- This is not adding T. If your training capacity feels capped, that's an androgen-side question — re-check your TRT trough, free T, and SHBG before assuming the GH stack is the lever to push.
- Skin reactions at injection sites are normal early. Mild redness or a small wheal at the SubQ site clears within an hour and resolves entirely within the first 2 weeks as the tissue accommodates.
The practitioner corpus treats this stack as the workhorse GH-axis intervention for body recomposition on TRT. Track IGF-1 at week 6, track sleep depth nightly, and adjust dose within the 100–200 mcg Ipamorelin window based on what your labs and your recovery tell you.